Shares of Assembly Biosciences, Inc. (NASDAQ: ASMB) have received a consensus recommendation of “Moderate Buy” from seven ratings firms currently covering the stock, according to a report from Marketbeat. The average target price set by these analysts is $41.75 for the next twelve months, indicating a potential upside for investors.
Among the analysts, one has issued a sell rating, one a hold rating, while five have recommended buying the stock. Recently, several analysts have provided insights into Assembly Biosciences. On December 22, 2023, HC Wainwright reiterated a buy rating and set a target price of $50.00. Meanwhile, Mizuho established a price objective of $40.00 and rated the stock as “outperform” in a report released on November 20, 2023. In contrast, Weiss Ratings maintained a “sell (D-)” rating on January 21, 2024.
Institutional Investors Adjust Positions
A number of hedge funds and institutional investors have recently modified their stakes in Assembly Biosciences. For example, Informed Momentum Co LLC increased its investment by 1.6% in the fourth quarter, now holding 29,523 shares valued at approximately $1,004,000. Similarly, ADAR1 Capital Management LLC raised its position by 4.2%, resulting in ownership of 19,747 shares worth $672,000 after acquiring an additional 800 shares.
Other noteworthy adjustments include Geode Capital Management LLC, which increased its stake by 0.9% to 131,307 shares valued at $4,468,000, and Palumbo Wealth Management LLC, which lifted its stake by 7.2% to 37,305 shares worth $1,269,000. Finally, Bank of America Corp DE dramatically boosted its position by 6,382.7% during the third quarter, now owning 3,371 shares valued at $86,000 after acquiring an additional 3,319 shares.
Overall, institutional investors now hold 19.92% of Assembly Biosciences’ stock, reflecting a growing interest from larger financial entities.
Company Overview and Research Focus
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for infections caused by the hepatitis B virus (HBV) and hepatitis D virus (HDV). The company specializes in small-molecule modulation of viral proteins and host-targeted pathways aimed at achieving sustained viral suppression and potential functional cures.
Its research methodology encompasses medicinal chemistry, structural biology, and translational virology, advancing its pipeline from early discovery stages to clinical development. The company’s leading programs include core protein allosteric modulators (CpAMs) that disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors specifically targeting the HDV lifecycle.
Investors and stakeholders are closely monitoring developments surrounding Assembly Biosciences, especially with the recent fluctuations in analyst ratings and institutional investment patterns. As the company continues its research and development efforts, its stock performance will likely remain a topic of interest in the biotechnology sector.
